Background Nivolumab plus ipilimumab or nivolumab alone resulted in longer progression-
free and overall survival than ipilimumab alone in a trial involving patients with advanced …

Background Nivolumab (a programmed death 1 [PD-1] checkpoint inhibitor) and ipilimumab
(a cytotoxic T-lymphocyte–associated antigen 4 [CTLA-4] checkpoint inhibitor) have been …

Background Nivolumab combined with ipilimumab resulted in longer progression-free
survival and a higher objective response rate than ipilimumab alone in a phase 3 trial …

Background Nivolumab and ipilimumab are immune checkpoint inhibitors that have been
approved for the treatment of advanced melanoma. In the United States, ipilimumab has …

Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab
in Patients With Advanced Melanoma - PMC Back to Top Skip to main content NIH NLM Logo …

Background Previously reported results from the phase 3 CheckMate 067 trial showed a
significant improvement in objective responses, progression-free survival, and overall …

In recent years, new strategies for treating melanoma have been introduced, improving the
outlook for this challenging disease. One of the most important advances has been the …

The number of breast cancer survivors increases every year, thanks to the development of
new treatments and screening techniques. However, patients present with numerous side …

Background Dabrafenib plus trametinib improves clinical outcomes in BRAF V600-mutant
metastatic melanoma without brain metastases; however, the activity of dabrafenib plus …

Summary Background Previously, findings from CheckMate 238, a double-blind, phase 3
adjuvant trial in patients with resected stage IIIB–C or stage IV melanoma, showed …